Idera Pharmaceuticals, Inc.
505 Eagleview Blvd., Suite 212
Exton, Pennsylvania 19341
August 12, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
|Re:||Idera Pharmaceuticals, Inc.|
|Registration Statement on Form S-3|
|Filed August 4, 2020|
|File No. 333-240361|
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Idera Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on August 14, 2020, or as soon as practicable thereafter.
If the Securities and Exchange Commission has any questions concerning this request or requires any additional information, please contact Joanne R. Soslow of Morgan, Lewis & Bockius LLP at (215) 963-5262. The Company respectfully requests that it be notified of the effectiveness of the registration statement by a telephone call to Mrs. Soslow.
|IDERA PHARMACEUTICALS, INC.|
|By:||/s/ Bryant D. Lim|
|Name:||Bryant D. Lim|
|Title:||Senior V.P., General Counsel|
|cc:||Joanne R. Soslow, Morgan, Lewis & Bockius LLP|